We are proud to announce that Roche has become a founding partner in the next phase of BaseLaunch. With this commitment, Roche renews its partnership with us. “We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas...

We are proud to announce that Roche has become a founding partner in the next phase of BaseLaunch. With this commitment, Roche renews its partnership with us. “We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas...

Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later this year for validation of the Antibody-Catch.™ Download the press release here. ...

There is an opportunity to participate in a research study interview taking place for those with knowledge of the biopharmaceutical industry in Switzerland. The research should lead to the development of taxonomy of biopharmaceutical ecosystems, which may be used as a benchmark for firms and regions....

We are supporting an exciting project that exploits the role and vulnerabilities of circulating tumor cell clusters, major mediators of metastasis. The team is developing an entirely novel concept in cancer therapeutics, aiming to generate novel anti-cancer agents targeting circulating tumor cell clusters, leading to...

From our partner, KPGM: Proving an online knowledge base for the COVID-19 times.  KPMG has put together an online resource page for these challenging and uncertain times. The resources include:  -  A Covid-19 legal Hotline, where you can ask your legal questions and get free advice-  Recent...

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and Reference Capital, with the existing investors joining as well. To progress into the clinical phase, T3 appoints Claire Barton as...